Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Difference in Immunogenic Responses to COVID-19 Vaccines in Patients With Cancer Receiving Chemotherapy Versus Nonchemotherapy Treatment.
Tantiyavarong W, Sungkasubun P, Chaiwiriyawong W, Supavavej A, Limpawittayakul P, Weerasubpong B, Siripaibun J, Phanthunane C, Lamlertthon W, Ungtrakul T, Tawinprai K, Tantiyavarong P, Samdaengpan C. Tantiyavarong W, et al. Among authors: tawinprai k. JCO Glob Oncol. 2023 Feb;9:e2200331. doi: 10.1200/GO.22.00331. JCO Glob Oncol. 2023. PMID: 36821802 Free PMC article.
Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial.
Tawinprai K, Siripongboonsitti T, Porntharukchareon T, Wittayasak K, Thonwirak N, Soonklang K, Sornsamdang G, Auewarakul C, Mahanonda N. Tawinprai K, et al. Vaccine. 2022 Mar 15;40(12):1761-1767. doi: 10.1016/j.vaccine.2022.02.019. Epub 2022 Feb 21. Vaccine. 2022. PMID: 35210118 Free PMC article. Clinical Trial.
Persistence of immunogenicity, contributing factors of an immune response, and reactogenicities after a single dose of the ChAdOx1 (AZD1222) COVID-19 vaccine in the Thai population.
Tawinprai K, Siripongboonsitti T, Porntharukchareon T, Dechates B, Monprach H, Sornsamdang G, Wittayasak K, Soonklang K, Mahanonda N. Tawinprai K, et al. Hum Vaccin Immunother. 2022 Dec 31;18(1):2035573. doi: 10.1080/21645515.2022.2035573. Epub 2022 Mar 3. Hum Vaccin Immunother. 2022. PMID: 35240945 Free PMC article.
Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines.
Cohen G, Jungsomsri P, Sangwongwanich J, Tawinprai K, Siripongboonsitti T, Porntharukchareon T, Wittayasak K, Thonwirak N, Soonklang K, Sornsamdang G, Auewarakul C, Mahanonda N. Cohen G, et al. Among authors: tawinprai k. Hum Vaccin Immunother. 2022 Nov 30;18(5):2052525. doi: 10.1080/21645515.2022.2052525. Epub 2022 Mar 24. Hum Vaccin Immunother. 2022. PMID: 35323079 Free PMC article.
Safety and Immunogenicity of the BBIBP-CorV Vaccine in Adolescents Aged 12 to 17 Years in the Thai Population: An Immunobridging Study.
Tawinprai K, Siripongboonsitti T, Porntharukchareon T, Vanichsetakul P, Thonginnetra S, Niemsorn K, Promsena P, Tandhansakul M, Kasemlawan N, Ruangkijpaisal N, Banomyong N, Phattraprayoon N, Ungtrakul T, Wittayasak K, Thonwirak N, Soonklang K, Sornsamdang G, Mahanonda N. Tawinprai K, et al. Vaccines (Basel). 2022 May 19;10(5):807. doi: 10.3390/vaccines10050807. Vaccines (Basel). 2022. PMID: 35632562 Free PMC article.
Reactogenicity, immunogenicity, and humoral immune response dynamics after the third dose of heterologous COVID-19 vaccines in participants fully vaccinated with inactivated vaccine.
Tawinprai K, Siripongboonsitti T, Porntharukchareon T, Wittayasak K, Thonwirak N, Soonklang K, Sornsamdang G, Auewarakul C, Mahanonda N. Tawinprai K, et al. Expert Rev Vaccines. 2022 Dec;21(12):1873-1881. doi: 10.1080/14760584.2022.2099380. Epub 2022 Jul 13. Expert Rev Vaccines. 2022. PMID: 35792752 Clinical Trial.
Immunogenicity evaluation of ChAdox1 nCov-19 (AZD1222) vaccine in solid cancer patients in Chulabhorn Hospital.
Limpawittayakul P, Sungkasubun P, Chaiwiriyawong W, Supavavej A, Weerasubpong B, Siripaibun J, Phanthunane C, Lamlertthon W, Ungtrakul T, Tawinprai K, Tantiyavarong W, Samdaengpan C. Limpawittayakul P, et al. Among authors: tawinprai k. Hum Vaccin Immunother. 2022 Nov 30;18(6):2104058. doi: 10.1080/21645515.2022.2104058. Epub 2022 Aug 17. Hum Vaccin Immunother. 2022. PMID: 35976687 Free PMC article.
Safety after BBIBP-CorV (Sinopharm) COVID-19 Vaccine in Adolescents Aged 10-17 Years in Thailand.
Thonginnetra S, Tawinprai K, Niemsorn K, Promsena P, Tandhansakul M, Kasemlawan N, Ruangkijpaisal N, Banomyong N, Phattraprayoon N, Rangkakulnuwat P, Vanichsetakul P, Ungtrakul T, Wittayasak K, Thonwirak N, Soonklang K, Mahanonda N. Thonginnetra S, et al. Among authors: tawinprai k. Vaccines (Basel). 2022 Oct 21;10(10):1765. doi: 10.3390/vaccines10101765. Vaccines (Basel). 2022. PMID: 36298630 Free PMC article.
Immunogenicity and reactogenicity of heterologous prime-boost vaccination with inactivated COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccines, a quasi-experimental study.
Tawinprai K, Jungsomsri P, Pinijnai O, Tavonvunchai F, Lievjaroen A, Suwannaroj P, Siripongboonsitti T, Porntharukchareon T, Sornsamdang G, Ungtrakul T. Tawinprai K, et al. Hum Vaccin Immunother. 2023 Dec 31;19(1):2206360. doi: 10.1080/21645515.2023.2206360. Epub 2023 May 4. Hum Vaccin Immunother. 2023. PMID: 37140889 Free PMC article.
25 results